Guggenheim Initiates Coverage On Rhythm Pharmaceuticals with Buy Rating, Announces Price Target of $70
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has initiated coverage on Rhythm Pharmaceuticals with a Buy rating and set a price target of $70.
October 21, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim has initiated coverage on Rhythm Pharmaceuticals with a Buy rating and a price target of $70, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $70 by Guggenheim suggests a positive sentiment towards Rhythm Pharmaceuticals. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100